KAPA Company Profile and Key Details

KAPA has shown mixed momentum, losing -0.57% over the past week and -24.59% over the past quarter, though year-to-date performance is up 23.21%. Short-term trend indicators are bullishly aligned (SMA20 -9.42%, SMA50 -22.93%, SMA200 -38.59%). The stock’s 14-day RSI is 36.42 (weak momentum), while the ATR of 0.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -73.82% below its high and over 38.07% above its low. Average 10-day trading volume of 6.57 million shares is significantly above the 3-month average of 1.11 million, indicating heightened recent market interest.

Kairos Pharma, Ltd. has 20.74 million shares outstanding. The public float is 11.81 million shares, elevated short interest at 8.61% of float. This equals 869.28 thousand shares. The short ratio is 0.07 days. Institutional investors hold 13.52% of the float. Insiders own 39.86%. Yu John S holds 5.34 million shares, Murali Ramachandran has 133.06 thousand shares and Samuelson Doug has 60.80 thousand shares.

Kairos Pharma, Ltd. generated EPS of -$0.30 over the past year. Five-year average earnings growth is -23.37%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $9.00. The high target offers 2547.06% upside. The low target suggests 2547.06% downside. The mean target is $9.00. This offers 2547.06% upside. Kairos Pharma, Ltd. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 13, 2026, missed forecasts by 14.29%. The prior quarter beat by 264.08%. Over the last six quarters, Apple has recorded several small beats. These include 43.82% in February 26, 2025.

Kairos Pharma, Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.24. This means the shares are trading above this model’s fair value.

Kairos Pharma, Ltd. (AMEX:KAPA) closed at $0.34 USD, gaining $0.02 (6.89%) from the previous close of $0.32. The stock is currently mid-range between its 52-week high and low $0.30 and $2.11. With a market capitalization of about $7.28 million, Kairos Pharma, Ltd. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.50). Key stats such as the average daily volume over the past year has been around 493.36 thousand shares, trading with heavier-than-usual volume. Headquartered in Los Angeles, CA, Kairos Pharma, Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO John S. Yu, the company employs approximately 4 people and listed since September 16, 2024. Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer.

Kairos Pharma, Ltd. trades at a P/E ratio of -1.15, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.36 suggesting the stock is closer to book value. The P/FCF stands at -1.96, also below market averages.

Our AI price prediction model suggests that Kairos Pharma, Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -17.62%, with price expected at $0.28 by July 29, 2026, within a range of $0.25 to $0.30 3-Month Outlook: Projected fall of -26.45%, reaching $0.25 by October 12, 2026, with a range of $0.20 to $0.30. 1-Year Outlook: Projected gain of 494.29%, with price at $2.02 by July 15, 2027, within a range of $0.00 to $2.48.

Kairos Pharma, Ltd. (AMEX:KAPA) shares are up 23.21% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Kairos Pharma, Ltd. trading at a premium to the broader market with a P/E of -1.15. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.88, suggesting 2512.53% upside. Our AI forecast model points to short-term weakness (-17.62% over two weeks), a medium-term fall (-26.45% over three months), and a longer-term gain (494.29% over one year), with expected trading ranges indicating moderate volatility.